ICYMI: New study answers the age old question, “Does R&D really justify high drug costs?” (Spoiler alert: the answer is no.)
ICYMI – May 15, 2015 ***** The New England Journal of Medicine: “T… Read More
ICYMI – May 15, 2015 ***** The New England Journal of Medicine: “T… Read More
May 14, 2015 The House Energy and Commerce Committee released an updated… Read More
May 13, 2015 New Drug Report Reveals Drug Costs Top $50,000/year for Over Half… Read More
ICYMI May 5, 2015 The New York Times: Runaway Drug Prices How companies set… Read More
April 28, 2015 Note: Distributing the New York Times article below is not an… Read More
Reaction from National Coalition on Health Care President and CEO John Rother… Read More
It appears that spending on prescription medicines will continue to defy the laws of gravity, according to a new report from IMS Health Institute for Informatics. Read More
A great deal of analysis has been published on the causes of the health care spending slowdown system-wide — including in the pages of Health Affairs. Read More
Harvoni’s launch brought new howls about price gouging from insurers and a broad coalition of health care groups. They warn that the drugs, no matter how revolutionary, are ultimately unaffordable given the estimated 3 million Americans who may be infected with hepatitis C. Read More
Now that the FDA has approved the Harvoni treatment from Gilead Sciencesand a $94,500 price for a 12-week regimen has been established, attention is turning toward AbbVie and the steps the big drug maker must take to win market share. Read More
60 Minutes, the most successful news program in American history… Read More
In an effort to blunt the high price of hepatitis C treatments… Read More